Is Vandetanib a chemotherapy drug?

Vandetanib is different from traditional chemotherapy drugs in that it is a targeted therapy drug rather than a chemotherapy drug. Chemotherapy drugs usually kill rapidly dividing cells, including cancer cells and some healthy cells, causing many systemic side effects, such as hair loss, bone marrow suppression, gastrointestinal reactions, etc. In contrast, vandetanib works by targeting specific molecular signaling pathways, focusing on blocking the key roles of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET proto-oncogene in tumor growth and metastasis. Its treatment strategy is based on molecular targeting and can precisely intervene in abnormal signaling to slow tumor progression while maximizing the protection of normal tissue functions.

As a multi-target tyrosine kinase inhibitor, the therapeutic concept of vandetanib is to inhibit the driving mechanism of tumors rather than simply killing cells. This targeting mechanism makes it advantageous in terms of tolerability, long-term management and treatment, especially for patients with medullary thyroid cancer with RET mutations or abnormal expression of VEGFR/EGFR. Clinical data show that vandetanib can delay disease progression, improve patients' quality of life, and reduce the risk of severe toxic side effects common with traditional chemotherapy.

However, although vandetanib is not a traditional chemotherapy, it still has drug-specific side effects and requires regular monitoring of electrocardiogram, blood pressure, liver and kidney function and other indicators to ensure safe use. Therefore, in clinical practice, vandetanib is usually used under the guidance of a doctor, and a treatment plan is developed based on the patient's genetic testing and overall health status. Taken together, vandetanib is an important representative of modern molecular targeted therapy. Its precise mechanism and safety make it different from traditional chemotherapy drugs, making it an important choice for the treatment of specific tumors such as medullary thyroid cancer (thyroid cancer).

Reference materials:https://www.drugs.com/caprelsa.html